AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)
Brief description of study
The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes. The use of apixaban for stroke prevention in ischemic stroke patients like you, without atrial fibrillation, is not approved by the U.S. Food and Drug Administration (FDA) and is considered investigational in this research study. Aspirin is the standard of care blood thinner used for stroke prevention in patients
Clinical Study Identifier: s17-01117
ClinicalTrials.gov Identifier: NCT03192215
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
